Pulmonary Arterial Hypertension News and Research

RSS
Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Pioneering research paves way for new treatments for pulmonary arterial hypertension

Pioneering research paves way for new treatments for pulmonary arterial hypertension

GeneTex to introduce new antibody against hypoxia-inducible factor 1alpha

GeneTex to introduce new antibody against hypoxia-inducible factor 1alpha

Healthcare announces important changes to the U.S. product label for Optison

Healthcare announces important changes to the U.S. product label for Optison

PhaseBio commences Glymera Phase 2b study in type 2 diabetes

PhaseBio commences Glymera Phase 2b study in type 2 diabetes

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

VHVI now offers new minimally invasive, catheter-based approach to dissolve pulmonary embolism

VHVI now offers new minimally invasive, catheter-based approach to dissolve pulmonary embolism

AHA statement addresses varied cardiac evaluation and management of transplant patients

AHA statement addresses varied cardiac evaluation and management of transplant patients

Health Canada approves XIAFLEX for Dupuytren's contracture

Health Canada approves XIAFLEX for Dupuytren's contracture

UCLA Heart Transplant Program performs 2,000th heart transplant surgery

UCLA Heart Transplant Program performs 2,000th heart transplant surgery

PhaseBio raises $48.4M in Series B financing

PhaseBio raises $48.4M in Series B financing

Sarcoidosis accounts for 25% of all deaths in African-American women

Sarcoidosis accounts for 25% of all deaths in African-American women

Inhibition of PBEF could be potential therapeutic target for pulmonary hypertension

Inhibition of PBEF could be potential therapeutic target for pulmonary hypertension

New report provides detailed criteria for rational and timely use of cardiac catheterization

New report provides detailed criteria for rational and timely use of cardiac catheterization

Sildenafil may improve cardiac function in children, young adults with single ventricle defects

Sildenafil may improve cardiac function in children, young adults with single ventricle defects

Combination of Velcade and Fasudil could treat NSCLC

Combination of Velcade and Fasudil could treat NSCLC

TGA approves Ikaria’s LUCASSIN to treat Hepatorenal Syndrome Type 1

TGA approves Ikaria’s LUCASSIN to treat Hepatorenal Syndrome Type 1

Synthon receives tentative approval for tadalafil tablets

Synthon receives tentative approval for tadalafil tablets

Lee's Pharma licenses rights to commercialize PL2200 Aspirin in China

Lee's Pharma licenses rights to commercialize PL2200 Aspirin in China

Public service announcement on pediatric pulmonary hypertension

Public service announcement on pediatric pulmonary hypertension

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.